We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App




Misonix Sells Sonablate 500 Console and Sonatherm 600 to US HIFU

By HospiMedica International staff writers
Posted on 07 Jun 2010
Print article
Misonix Inc. (MSON; Farmingdale, NY, USA), a leading developer, manufacturer, and marketer of ultrasonic surgical devices, has agreed to sell its "Focus Surgery” related assets plus its European distribution rights to US HIFU LLC (Charlotte, N.C., USA), a privately held healthcare company focused on treating primary and recurrent prostate cancer using HIFU, for US$5.8 million.

The transaction entitles US HIFU with rights to acquire Sonatherm 600, a laparoscopic HIFU system used in the ablation of certain soft tissues. Furthermore, US HIFU will hold distribution rights for Misonix's SB500 console, with Misonix retaining intellectual property rights to the three HIFU patents, which were acquired from ProRhythm in June 2009.

The agreement allows Misonix to focus on minimizing additional operating costs and in developing its own proprietary medical devices such as the HIFU transducers and lens technology. Misonix's President and CEO, Michael A. McManus, Jr. commented on the deal "Going forward, we will be a dedicated ultrasonic surgical device company developing, manufacturing and selling only devices we own outright."

The acquisition of the Sonatherm 600 is a major step for US HIFU; this being the company's first significant device, which has received the mandatory US Food and Drug Administration (FDA; Atlanta, GA, USA), clearance, for commercialization in the United States. Sonatherm is a high intensity focused ultrasound (HIFU) treatment of soft tissue, developed by Misonix after it acquired worldwide rights for the product from Focus Surgery, Inc. in July 2008.

The addition of Sonablate HIFU (a minimally invasive medical device used for the treatment of prostate cancer) will add momentum to the US HIFU's plans for a Pan European initiative to showcase the enhanced efficacy of Sonablate HIFU. This device, which is authorized and commercially available in more than 30 other countries, is in its final phase of the FDA's clinical trials.

"This transaction brings Sonablate manufacturing, and research and development together again under one roof… allowing for increased efficiency operationally and an expansion of our HIFU product portfolio," said US HIFU's CEO Steve Puckett, Jr.

Related Links:

Misonix Inc.
US HIFU



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Phototherapy Eye Protector
EyeMax2
New
Hospital Data Analytics Software
OR Companion

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.